Investor Presentaiton
HANQUYOU (Trastuzumab): Sales Growth 58% YoY
Henlius
(注射用 曲妥珠斗
仅整优
で公
2.74B RMB*
Henlius
Revenue in 2023
Henlius
注射用曲妥珠单抗
汉曲优 Ⓡ
注射用曲妥珠单抗
汉曲优 Ⓡ
150毫克/瓶 01瓶装
60毫克/瓶 51瓶装
REI
.
International quality
First approved trastuzumab biosimilar in China
First "Chinese nationality" mAb biosimilar approved
in Europe
BLA under FDA review; expected to be the first
"Chinese nationality" biosimilar approved in all three
regions of China, Europe, and the US
Launched in 40+ countries and regions
Multiple specifications
Tailored for HER2-positive breast cancer patients in
China with flexible specs to fit with personalized
dosage and reduce residual fluid waste
No preservatives, solution preparation upon product
usage to improve safety
•
Improved patient medication safety and good
practice for drug administration
•
Strong growth momentum
1.73
2022
+58%
In Billion RMB
2.74
2023
•
•
150mg specification: completed NRDL and tendering
platform listing for all provinces in China
60mg specification: completed NRDL listing for all
provinces and tendering platform listing in 30 provinces
by the end of February 2024
Commercial team with ~600 professionals, covering 6
major sales regions and ~3,700 hospitals in China
Zercepac 150mg
der for concent
astuzumab
after reconst
clusion
Ore is sortains 159mg
Tab A
onl
danir
contars 2 rg
Hus sontairs Lathe
cebetales tyre
Rest
e
Rewe package te
beds an
Kong to the schrand
cd des
Stove in a retigerat
Zercepac 150 mg
powder for concentrate
for solution for infusion
trastuzumab
For intravenous use only
after reconstruton and clution
1 vial
accord
Ⓒ Target: HER2 Indications:
·
•
Early stage breast cancer
Metastatic breast cancer
Metastatic gastric cancer
Drug Specifications:
150mg/bottle (China, overseas)
60mg/bottle (China, overseas)
420mg/bottle (overseas)
2 Henlius
ZercepacⓇ in Europe
TuzucipⓇ and TrastucipⓇ in Australia
*Sum of sales revenue of HANQUYOU in China and overseas, and drug substance of trastuzumab
10
2024 Henlius.View entire presentation